Therapeutic area
Endocrinology and women's health
Last checked: Nov 19, 2026Source: Drugs@FDA, ClinicalTrials.govMethods & limitations
Approvals since 2023
14
Originals, plus breakthrough or accelerated new uses
Recruiting Phase 2
8
Industry-sponsored
Recruiting Phase 3
8
Industry-sponsored
Recruiting Phase 4 (post-approval)
2
Industry-sponsored
Recent approvals
- Gwyn Lo (Ethinyl Estradiol, Norelgestromin) · Viatris Specialty Jul 28, 2026
- Lumvoa (Veligrotug-Vvze) · Viridian Therapeutics INC NovelBreakthrough therapyPriority reviewJun 26, 2026
To treat thyroid eye disease
- Veppanu (Vepdegestrant) · Rigel Pharms NovelMay 1, 2026
To treat estrogen receptor-positive, human epidermal growth factor receptor 2-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy
- Lynkuet (Elinzanetant) · Bayer Hlthcare NovelOct 24, 2025
To treat moderate-to-severe vasomotor symptoms due to menopause
- Inluriyo (Imlunestrant Tosylate) · Eli Lilly and CO NovelSep 25, 2025
To treat estrogen receptor-positive, human epidermal growth factor receptor 2-negative, estrogen receptor-1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy
- Palsonify (Paltusotine Hydrochloride) · Crinetics NovelOrphanSep 25, 2025
To treat acromegaly in adults who had an inadequate response to surgery and/or for whom surgery is not an option
- Miudella (Copper) · Sebela Womens Hlth Feb 24, 2025
- Crenessity (Crinecerfont) · Neurocrine NovelBreakthrough therapyPriority reviewOrphanDec 13, 2024
To treat classic congenital adrenal hyperplasia
- Yorvipath (Palopegteriparatide) · Ascendis Pharma Bone NovelPriority reviewOrphanAug 9, 2024
To treat hypoparathyroidism
- Rezdiffra (Resmetirom) · Madrigal NovelBreakthrough therapyAccelerated approvalPriority reviewMar 14, 2024
To treat noncirrhotic non-alcoholic steatohepatitis with moderate to advanced liver scarring
- Ngenla (Somatrogon-Ghla) · Pfizer Ireland Pharmaceuticals NovelOrphanJun 27, 2023
To treat growth failure due to inadequate secretion of endogenous growth hormone
- Veozah (Fezolinetant) · Astellas NovelPriority reviewMay 12, 2023
To treat moderate to severe hot flashes caused by menopause
- Adrenalin (Epinephrine) · Ph Health Apr 21, 2023
- Orserdu (Elacestrant Hydrochloride) · Stemline Therap NovelPriority reviewJan 27, 2023
To treat estrogen receptor-positive, human epidermal growth factor receptor 2-negative, ESR1-mutated, advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy
Recruiting trials by phase
Industry-sponsored drug and biologic trials.
Most approvals since then, by company
Drugs in development
Investigational drugs in Phase 2 and 3 trials for conditions in this area, most trials first.
- GiredestrantRO7197597, GDC-9545Phase 316 trials
Roche (Genentech) · Early Breast Cancer, Breast Cancer, Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer
- ZanzalintinibXL092Phase 311 trials
Exelixis · Colorectal Cancer, Renal Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
- AtirmociclibPF-07220060Phase 39 trials
Pfizer · Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer
- LHRH AgonistPhase 36 trials
Roche (Genentech) · Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer, Early Breast Cancer, Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer
- LUM-201Phase 36 trials
Lumos Pharma · Growth Hormone Deficiency, Growth Hormone Deficiency (GHD), Obesity & Overweight
- MHB018APhase 36 trials
Minghui Pharmaceutical (Hangzhou) Ltd · Thyroid Eye Disease (TED), Thyroid Eye Disease, TED, Thyroid Associated Ophthalmopathies
- CRN04894AtumelnantPhase 35 trials
Crinetics Pharmaceuticals Inc. · Congenital Adrenal Hyperplasia, Classic Congenital Adrenal Hyperplasia, Cushing Syndrome
- VRDN-003ZL-1109Phase 35 trials
Viridian Therapeutics, Inc. · Thyroid Eye Disease, Thyroid Eye Disease (TED)
- InpegsomatropinPhase 34 trials
Xiamen Amoytop Biotech Co., Ltd. · Turner Syndrome, Idiopathic Short Stature, Adult Growth Hormone Deficiency
- ZN-c3azenosertibPhase 34 trials
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc · Ovarian Cancer, High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer, Uterine Serous Carcinoma
- AL2846Phase 33 trials
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Thyroid Cancer, Differentiated Thyroid Cancer, Advanced Lung Cancer
- BatoclimabIMVT-1401Phase 33 trials
Immunovant Sciences GmbH · Thyroid Eye Disease, Graves Disease
- CAM2029octreotide depotPhase 33 trials
Camurus AB · Polycystic Liver Disease, Gastro-enteropancreatic Neuroendocrine Tumor, Acromegaly
- EncaleretCLTX-305Phase 33 trials
Calcilytix Therapeutics, Inc., a BridgeBio company · Autosomal Dominant Hypocalcemia Type 1 (ADH1), Autosomal Dominant Hypocalcemia (ADH), Hypoparathyroidism
- IBI311Phase 33 trials
Innovent Biologics (Suzhou) Co. Ltd. · Thyroid Eye Disease, Thyroid Eye Disease, TED
Largest recruiting Phase 3 trials
- A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids or EndometriosisPivotal-lookingRecruiting
Sumitomo Pharma Switzerland GmbHIndustry
NCT05862272 · 1,000 participants (planned) · Start Aug 14, 2023 · Primary completion Jul 2029
Drug: Relugolix Combination Tablet · For: Uterine Fibroids; Endometriosis
Sites: Mobile, Alabama; Chandler, Arizona; Mesa, Arizona · 120 sites in all
- Evaluate the Efficacy and Safety of HMI-115 in Women With Moderate to Severe Endometriosis-associated PainPivotal-lookingRecruiting
Hope Medicine (Nanjing) Co., LtdIndustry
NCT07318688 · 540 participants (planned) · Start Jan 29, 2026 · Primary completion Mar 1, 2028
Drug: HMI-115; Placebo · For: Endometriosis
Sites: Beijing, China; Nanning, China; Suzhu, China · 5 sites in all
- An Open-Label, Single-Arm Study to Investigate the Efficacy and Safety of North Star Desiccated Porcine Thyroid Extract Tablets.Pivotal-lookingRecruiting
Neuvosyn Laboratories, LLCIndustry
NCT07747103 · 466 participants (planned) · Start Jun 30, 2026 · Primary completion Nov 2027
Drug: Desiccated Porcine Thyroid Extract Tablets · For: Hypothyroidism
Sites: Modesto, California; Redding, California; San Diego, California · 25 sites in all
- A Comparative Study to Valuating the Efficacy and Safety of QL1206 and Prolia®Pivotal-lookingRecruiting
Qilu Pharmaceutical Co., Ltd.Industry
NCT07062978 · 278 participants (planned) · Start Jun 27, 2025 · Primary completion Jan 2027
Drug: QL1206; Prolia® · For: Postmenopausal Women With Osteoporosis at High Risk of Fracture
Sites: Guizhou, China
- GB06 Phase III Trial for Pediatric Growth Hormone DeficiencyPivotal-lookingRecruiting
Kexing Biopharm Co., Ltd.Industry
NCT07553351 · 192 participants (planned) · Start Jun 6, 2026 · Primary completion Jul 25, 2028
Drug: GB06; Norditropin®FlexProTM · For: Growth Hormone Deficiency (GHD); Growth Hormone Deficiency in Children; Growth Hormone Deficiency, Pediatric
Sites: Chengdu, China
- Phase 3 Study of LUM-201 in Children With Growth Hormone DeficiencyPivotal-lookingRecruiting
Lumos PharmaIndustry
NCT06948214 · 150 participants (planned) · Start May 20, 2026 · Primary completion Dec 2027
Drug: LUM-201 · For: Growth Hormone Deficiency (GHD)
Sites: Birmingham, Alabama; Madera, California; Orange, California · 55 sites in all
- A Study to Assess the Efficacy and Safety of Debio 4126 in Participants With Acromegaly Previously Treated With Somatostatin AnalogsPivotal-lookingRecruiting
Debiopharm International SAIndustry
NCT06930625 · 119 participants (planned) · Start Nov 26, 2025 · Primary completion Jun 2028
Drug: Debio 4126; Placebo · For: Acromegaly
Sites: Los Angeles, California; Chicago, Illinois; Boston, Massachusetts · 74 sites in all
- A Study to Confirm if Fezolinetant Helps to Reduce Hot Flashes in Indian Women Going Through MenopausePivotal-lookingRecruiting
Astellas Pharma IncAstellas (ALPMY)
NCT07829653 · 100 participants (planned) · Start Oct 23, 2026 · Primary completion Mar 31, 2028
Drug: Fezolinetant · For: Hot Flashes
Sites: Bengaluru, India
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.